Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA
This article was originally published in The Tan Sheet
Executive Summary
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.
You may also be interested in...
FDA-Initiated OTC Switches Could Be Based On Foreign Data – McClellan
FDA may rely on a drug's foreign OTC marketing experience to determine whether an Rx product should be switched OTC in the U.S. without sponsor consent, Commissioner Mark McClellan, MD/PhD, said at a Manhattan Institute roundtable discussion for buyside analysts May 16
CPSC Rx-To-OTC Switch Final Rule Published As Gall Loses Chair Nomination
Manufacturers cannot be ensured confidentiality when submitting child-resistant packaging (CRP) exemption requests for oral Rx-to-OTC switches, the Consumer Product Safety Commission clarifies in its final rule requiring CRP for all such drugs.
ODE V Deputy Bull To Step In "As Needed" For Novartis-Bound DeLap
FDA Office of Drug Evaluation V Deputy Director Jonca Bull, MD is serving as the office's acting director in areas in which departing Director Robert DeLap, MD/PhD, has potential conflicts of interest.